Would you offer adjuvant immunotherapy to patients with stage II-III NSCLC who achieved a pathologic complete response from 3 cycles of neoadjuvant nivolumab + chemotherapy?

Approximately, 1/4 (24%) of patients in the CheckMate 816 trial treated with nivolumab + chemotherapy achieved a pathologic CR (compared to 2% with neoadjuvant chemo alone). The patients who did achieve a pathCR had the best EFS (although limited follow up to date; median EFS not reached, HR 0.13). ...

I agree and follow the CheckMate 816 protocol and would observe patients with routine surveillance following completion of neoadjuvant therapy and surgery. The unknown, pending further data, is the impact of additional therapy? Since we cannot know, we risk overtreatment by giving both neoadjuvant a...

No